Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications

Alzheimer's disease is the most common cause of dementia and its prevalence is expected to increase in the coming years. Therefore, accurate diagnosis is crucial for patients, clinicians and researchers. Neuroimaging techniques have provided invaluable information about Alzheimer's disease and, owing to recent advances, these methods will have an increasingly important role in research and clinical practice. The purpose of this article is to review recent neuroimaging studies of Alzheimer's disease that provide relevant information to clinical practice, including a new modality: in vivo amyloid imaging. Magnetic resonance imaging, single photon emission computed tomography and 18F-fluorodeoxyglucose-positron emission tomography are currently available for clinical use. Patients with suspected Alzheimer's disease are commonly investigated with magnetic resonance imaging because it provides detailed images of brain structure and allows the identification of supportive features for the diagnosis. Neurofunctional techniques such as single photon emission computed tomography and 18F-fluorodeoxyglucose-positron emission tomography can also be used to complement the diagnostic investigation in cases of uncertainty. Amyloid imaging is a non-invasive technique that uses positron emission tomography technology to investigate the accumulation of the β-amyloid peptide in the brain, which is a hallmark of Alzheimer's disease. This is a promising test but currently its use is restricted to very few specialized research centers in the world. Technological innovations will probably increase its availability and reliability, which are the necessary steps to achieve robust clinical applicability. Thus, in the future it is likely that amyloid imaging techniques will be used in the clinical evaluation of patients with Alzheimer's disease.

[1]  J O Rinne,et al.  Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.

[2]  Christos Davatzikos,et al.  Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI , 2009, NeuroImage.

[3]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[4]  D. Louis Collins,et al.  MRI-Based Automated Computer Classification of Probable AD Versus Normal Controls , 2008, IEEE Transactions on Medical Imaging.

[5]  Kiralee M. Hayashi,et al.  Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease , 2010, Neurobiology of Aging.

[6]  P. Lantos,et al.  Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies , 1999, British Journal of Psychiatry.

[7]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[8]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[10]  C. Jack,et al.  Boosting power for clinical trials using classifiers based on multiple biomarkers , 2010, Neurobiology of Aging.

[11]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[12]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[13]  V. Henderson,et al.  Diagnosis and Treatment of Alzheimer's Disease , 2005 .

[14]  S. Resnick,et al.  Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging , 2008, Neurobiology of Aging.

[15]  G. Busatto,et al.  Volumetric reduction of the corpus callosum in Alzheimer's disease in vivo as assessed with voxel-based morphometry , 2007, Psychiatry Research: Neuroimaging.

[16]  T. Iwatsubo,et al.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.

[17]  Markus Schwaiger,et al.  Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.

[18]  M. Brammer,et al.  Pattern Classification of Sad Facial Processing: Toward the Development of Neurobiological Markers in Depression , 2008, Biological Psychiatry.

[19]  G. Busatto,et al.  Voxel-based morphometry in Alzheimer’s disease , 2008, Expert review of neurotherapeutics.

[20]  Paul M. Thompson,et al.  Mapping hippocampal and ventricular change in Alzheimer disease , 2004, NeuroImage.

[21]  D. Knopman,et al.  Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI , 2009, Neurology.

[22]  P. Scheltens,et al.  Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline , 2007, European journal of neurology.

[23]  Clifford R. Jack,et al.  3 D maps frommultiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer ’ s disease , 2007 .

[24]  R. Murray,et al.  Pattern of neural responses to verbal fluency shows diagnostic specificity for schizophrenia and bipolar disorder , 2011, BMC psychiatry.

[25]  L. Schneider,et al.  Report of the task force on designing clinical trials in early (predementia) AD , 2010, Neurology.

[26]  Alain Giron,et al.  Differential automatic diagnosis between Alzheimer's disease and frontotemporal dementia based on perfusion SPECT images , 2009, Artif. Intell. Medicine.

[27]  PET e SPECT cerebrais na avaliação dos estados demenciais , 2001 .

[28]  A. Pfefferbaum,et al.  MR Diffusion Tensor Imaging: A Window into White Matter Integrity of the Working Brain , 2010, Neuropsychology Review.

[29]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[30]  Klemens Scheidhauer,et al.  Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  Nick C Fox,et al.  Automatic classification of MR scans in Alzheimer's disease. , 2008, Brain : a journal of neurology.

[32]  Dinggang Shen,et al.  COMPARE: Classification of Morphological Patterns Using Adaptive Regional Elements , 2007, IEEE Transactions on Medical Imaging.

[33]  H. Braak,et al.  Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[34]  G. Evin,et al.  Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides , 2002, Peptides.

[35]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[36]  Roman Filipovych,et al.  Semi-supervised pattern classification of medical images: Application to mild cognitive impairment (MCI) , 2011, NeuroImage.

[37]  Christopher Clark,et al.  Disease-modifying therapies for Alzheimer disease , 2007, Neurology.

[38]  C. Jack,et al.  3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. , 2007, Brain : a journal of neurology.

[39]  W. Klunk,et al.  Update on amyloid imaging: From healthy aging to Alzheimer’s disease , 2009, Current neurology and neuroscience reports.

[40]  J. Ramírez,et al.  SVM-based computer-aided diagnosis of the Alzheimer's disease using t-test NMSE feature selection with feature correlation weighting , 2009, Neuroscience Letters.

[41]  Ronald C Petersen,et al.  Detection of prodromal Alzheimer's disease , 2008, Annals of neurology.

[42]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[43]  Y. Zang,et al.  Voxel-based detection of white matter abnormalities in mild Alzheimer disease , 2006, Neurology.

[44]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[45]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[46]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[47]  Janaina Mourão Miranda,et al.  Investigating the predictive value of whole-brain structural MR scans in autism: A pattern classification approach , 2010, NeuroImage.

[48]  C. Rowe,et al.  Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.

[49]  J. Baron,et al.  Relationships between Hippocampal Atrophy, White Matter Disruption, and Gray Matter Hypometabolism in Alzheimer's Disease , 2008, The Journal of Neuroscience.

[50]  Ismo Räihä,et al.  Diagnosing cognitive impairment and dementia in primary health care -- a more active approach is needed. , 2003, Age and ageing.

[51]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[52]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[53]  A. Dale,et al.  Regional rates of neocortical atrophy from normal aging to early Alzheimer disease , 2009, Neurology.

[54]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[55]  W. Jagust,et al.  Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo , 2009, Behavioural neurology.

[56]  H. Engler,et al.  In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  Clifford R. Jack,et al.  Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies , 2008, NeuroImage.

[58]  G. Frisoni,et al.  Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment , 2007, Journal of Neurology.

[59]  Matthias L. Schroeter,et al.  Neural correlates of Alzheimer's disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients , 2009, NeuroImage.

[60]  E. Amaro,et al.  Use of SVM methods with surface-based cortical and volumetric subcortical measurements to detect Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[61]  Dewen Hu,et al.  Discriminative analysis of resting-state functional connectivity patterns of schizophrenia using low dimensional embedding of fMRI , 2010, NeuroImage.

[62]  Massimo Filippi,et al.  Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease , 2010, Human brain mapping.

[63]  G. Busatto,et al.  Neurostructural predictors of Alzheimer's disease: A meta-analysis of VBM studies , 2011, Neurobiology of Aging.

[64]  G. Linazasoro,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.